|66.10||-1.49||-2.20%||Vol 54.78K||1Y Perf 78.84%|
|Apr 16th, 2021 11:12 DELAYED|
|- -%||- -|
|Target Price||67.00||Analyst Rating||Strong Buy 1.33|
|Potential %||0.98||Finscreener Ranking||★★★★+ 56.26|
|Insiders Trans % 3/6/12 mo.||-100/-91/-94||Value Ranking||★★★★ 56.14|
|Insiders Value % 3/6/12 mo.||-100/-96/-97||Growth Ranking||★★+ 48.87|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-94/-96||Income Ranking||— -|
|Market Cap||3.02B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||93.61||Earnings Date||27th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Apr 2021|
|Estimated EPS Next Report||-0.38|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||268.03K|
|Avg. Monthly Volume||324.97K|
|Avg. Quarterly Volume||374.17K|
AtriCure Inc. (NASDAQ: ATRC) stock closed at 67.59 per share at the end of the most recent trading day (a 1.95% change compared to the prior day closing price) with a volume of 310.99K shares and market capitalization of 3.02B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 730 people. AtriCure Inc. CEO is Michael H. Carrel.
The one-year performance of AtriCure Inc. stock is 78.84%, while year-to-date (YTD) performance is 21.41%. ATRC stock has a five-year performance of 317.22%. Its 52-week range is between 34.04 and 68.29, which gives ATRC stock a 52-week price range ratio of 93.61%
AtriCure Inc. currently has a PE ratio of -57.40, a price-to-book (PB) ratio of 7.35, a price-to-sale (PS) ratio of 19.61, a price to cashflow ratio of 255.30, a PEG ratio of 2.32, a ROA of -7.29%, a ROC of -10.42% and a ROE of -14.13%. The company’s profit margin is -20.31%, its EBITDA margin is -16.30%, and its revenue ttm is $153.31 Million , which makes it $3.36 revenue per share.
Of the last four earnings reports from AtriCure Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. AtriCure Inc.’s next earnings report date is 27th Apr 2021.
The consensus rating of Wall Street analysts for AtriCure Inc. is Strong Buy (1.33), with a target price of $67, which is +0.98% compared to the current price. The earnings rating for AtriCure Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AtriCure Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AtriCure Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.25, ATR14 : 2.76, CCI20 : 125.93, Chaikin Money Flow : 0.19, MACD : 1.39, Money Flow Index : 65.54, ROC : 8.56, RSI : 55.73, STOCH (14,3) : 99.24, STOCH RSI : 1.00, UO : 56.82, Williams %R : -0.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AtriCure Inc. in the last 12-months were: Douglas J. Seith (Sold 62 719 shares of value $2 996 374 ), Justin J. Noznesky (Option Excercise at a value of $549 000), Justin J. Noznesky (Sold 66 794 shares of value $3 307 426 ), Mark A. Collar (Option Excercise at a value of $103 000), Mark A. Collar (Sold 14 000 shares of value $643 014 ), Mark R. Lanning (Option Excercise at a value of $51 500), Michael H. Carrel (Option Excercise at a value of $7 281 250), Michael H. Carrel (Sold 400 000 shares of value $22 475 129 ), Regina Groves (Sold 6 313 shares of value $264 073 ), Salvatore Privitera (Sold 14 500 shares of value $729 555 ), Scott W. Drake (Buy at a value of $500 669)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.